This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
by Zacks Equity Research
Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market as the first approved treatment for the condition.
IONSNegative Net Change AZNPositive Net Change GSKPositive Net Change BIIBPositive Net Change
biotechs medical pharmaceuticals
Here's Why You Should Add ANIX Stock to Your Portfolio Now
by Zacks Equity Research
Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phase II study and expanding intellectual property protection.
ANIXPositive Net Change AMRNPositive Net Change LQDANegative Net Change IMCRNegative Net Change
biotechs
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
by Zacks Equity Research
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
ABSIPositive Net Change LQDANegative Net Change IMCRNegative Net Change KVUENegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
by Zacks Equity Research
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
GILDNegative Net Change MRKPositive Net Change LQDANegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug
by Zacks Equity Research
Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.
VKTXPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Reasons Why Investors Should Consider Betting on Indivior Stock
by Zacks Equity Research
INDV's Sublocade reaches 500,000+ U.S. patients. Management expects faster 2026 growth through cost optimization and strong execution.
INDVNegative Net Change AMRNPositive Net Change LQDANegative Net Change IMCRNegative Net Change
biotechs
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
by Zacks Equity Research
Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.
GILDNegative Net Change MRKPositive Net Change LQDANegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
by Zacks Equity Research
Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.
RVMDPositive Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
by Zacks Equity Research
Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.
GALTNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Buy Stocks for June 24th
by Zacks Equity Research
BY, NVGS, NBIX, TFII and BG have been added to the Zacks Rank #1 (Strong Buy) List on June 24th, 2026.
BGNegative Net Change NBIXPositive Net Change NVGSNegative Net Change BYPositive Net Change TFIINegative Net Change
biotechs finance medical